UK conditionally approves Lilly’s Retsevmo® for RET-driven lung and thyroid cancers
The conditional marketing authorisation of Retsevmo® (selpercatinib) was based on…
The conditional marketing authorisation of Retsevmo® (selpercatinib) was based on positive results from the LIBRETTO-001 Phase I/II trial.